Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nextage TherapeuticsXTAE:NXTG 12 Buyback Yield % is 0.00 as of Sep. 12, 2026. GuruFocus rates XTAE:NXTG with a GF Score™ of 12/100 and a GF Value™ of ₪0.24 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 235 Drug Manufacturers companies, Nextage Therapeutics ranks worse than 425531.49% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Nextage Therapeutics Buyback Yield % Related Terms
Nextage Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Nextage Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTAE:NXTG vs ZTS, UTHR, VTRS: Buyback Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Nextage Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nextage Therapeutics Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nextage Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Nextage Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nextage Therapeutics (XTAE:NXTG) has a Buyback Yield % of 0.00 as of Sep. 12, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Nextage Therapeutics and its competitors. According to the industry distribution chart, Nextage Therapeutics ranks #999999 out of 235 companies in the Drug Manufacturers industry.
Is Nextage Therapeutics' Buyback Yield % too high?
Nextage Therapeutics' current Buyback Yield % is 0.00. Based on the distribution chart, Nextage Therapeutics ranks #999999 out of 235 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Nextage Therapeutics has a GF Score™ of 12/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nextage Therapeutics' Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Nextage Therapeutics ranks #999999 out of 235 companies for Buyback Yield %. This places Nextage Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Nextage Therapeutics and its competitors. Nextage Therapeutics's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nextage Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nextage Therapeutics (XTAE:NXTG) is currently considered Significantly Overvalued. The stock's GF Value™ is ₪0.24, compared to a current price of ₪0.44 — trading 83.3% above its estimated fair value. The current Buyback Yield % is 0.00. Nextage Therapeutics' overall GF Score™ is 12/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Nextage Therapeutics (XTAE:NXTG), the current Buyback Yield % is 0.00 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nextage Therapeutics (XTAE:NXTG) Overvalued in 2026?
Based on GuruFocus' analysis, Nextage Therapeutics stock appears to be overvalued.
The current stock price of ₪0.44 is trading 83.3% above its estimated GF Value™ of ₪0.24.
GuruFocus considers Nextage Therapeutics to be Significantly Overvalued.
Key valuation signals for XTAE:NXTG:
Buyback Yield %: 0.00
GF Value™: ₪0.24 vs. price of ₪0.44 (83.3% above fair value)
No single metric tells the full story. See the XTAE:NXTG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nextage Therapeutics Ltd is a holding company. The company, through its subsidiaries, is engaged in the development of biological marker, a molecule/gene, which when present in the body at abnormal levels indicates development of a disease. It is focused on the development and commercialization of cancer diagnostic products.
12GF Score
Get the complete analysis for XTAE:NXTG
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:NXTG has been successfully added to your 
